drugset / Trial / NCT06054815
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
Timeline
- Start
- 2023-09-14
- Primary completion
- 2024-10-24
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-1241 | Unknown | — | Oral |
| Subject | Sitagliptin | Small molecule | — | Oral |